Chemical structure of clarithromycin.
Find information on thousands of medical conditions and prescription drugs.

Clarithromycin

Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydia pneumoniae or TWAR), skin and skin structure infections, and, in HIV and AIDS patients to prevent, and to treat, disseminated Mycobacterium avium complex or MAC. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

In addition, it is sometimes used to treat Legionellosis.

Clarithromycin is available under several brandnames, for example Biaxin and Klacid.

History

Abbott Laboratories brought out clarithromycin in 1991.

Available forms

Clarithromycin is commonly administered in tablets (Biaxin®), extended-release tablets (Biaxin XL®), or oral suspension.

Mechanism of action

Clarithromycin prevents bacteria from growing, by interfering with their protein synthesis. Clarithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Clarithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophilae. Besides this bacteriostatic effect, clarithromycin also has bactericidal effect on certain strains such as Haemophilus influenzae, Streptococcus pneumoniae and Neisseria gonorrhoeae.

Pharmacokinetics

Unlike erythromycin, clarithromycin is acid-stable and can therefore be taken orally without being protected from gastric acids. It is readily absorbed, and diffused into most tissues and phagocytes. Due to the high concentration in phagocytes, clarithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations of clarithromycin is released. The concentration of clarithromycin in the tissues can be over 10 times higher than in plasma. Highest concentrations were found in liver and lung tissue.

Metabolism

Clarithromycin has a fairly rapid first-pass hepatic metabolism, i.e it is metabolised by the liver. However, this metabolite, 14-hydroxy clarithromycin is almost twice as active as clarithromycin. The half-life of clarithromycin is about 5 hours and 14-hydroxy clarithromycin's about 7 hours. Clarithromycin's and its metabolites' main routes of elimination are urinary and biliary excretion.

Side effects

Most common side-effects are gastrointestinal; diarrhea, nausea, abdominal pain and vomiting. Less common side-effects include headaches, rashes, alteration in senses of smell and taste.

Special Precautions

Allergic reactions can occur with clarithromycin use. People with a history of allergy, asthma, hay fever or hives seem to be more susceptible to these reactions. The reaction can be immediate and severe.

Allergic symptoms include wheezing, hives, itching, swelling, spasms in the throat and breathing tubes, joint and muscle pain, difficulty breathing, fever and skin rashes. Nausea and vomiting are not symptoms of an allergic reaction.

Read more at Wikipedia.org


[List your site here Free!]


Experimental pleurodesis: intrapleural injection of azythromycin, clarithromycin or levofloxacin
From CHEST, 10/1/05 by Renam U. Bumlai

PURPOSE: Pleurodesis is commonly used to treat recurrent pleural effusion or pueumothorax. The ideal agent for pleurodesis is still being sought. Previous studies demonstrated that intrapleural instillation of erythromycin, a macrolide antibiotic, could be a potential pleural sclerosing agent. There is no studies demonstrating the effect of quinolones as pleural sclerosing. The aim of this study was to evaluate the intrapleural injection of azythromycin, clarithromycin or levofloxacin as pleural sclerosing agents.

METHODS: Thirty rabbits, divided in 3 groups received, through a chest tube, intrapleural administration of azythromycin (15mg/kg), clarithromycin (15 mg/kg) or levofloxacin (10 mg/kg) in a total volume of 2ml. After 28 days the animals were sacrificed and the degree of pleural adhesions were evaluated in a score from 0 (no adhesions) to 4 (complete obliteration of pleural space). Pleurodesis are considered when score >3. We also evaluated the microscopic changes for inflammation and fibrosis in scores from 0 to 4 according to the intensity of process. Statistical analysis: Descriptive Analysis (mean + standard deviation) and Kruskall Wallis ANOVA.

RESULTS: After the intrapleural administration of azythromycin, clarithromycin or levofloxacin we observed a few macroscopic adhesions. The scores were 1.2 [+ or -] 0.5, 1.2 [+ or -] 1.0 and 1.0 [+ or -] 0.5 respectively, and no statistical difference were observed among the groups. The microscopic analysis of pleura and parenchyma showed discrete changes for all drugs, with a greater scores of pleural fibrosis in the clarithromycin group.

CONCLUSION: The intrapleural injection of azythromycin, clarithromycin or levofloxacin was ineffective in creating pleurodesis in our experimental model.

CLINICAL IMPLICATIONS: Macrolides or quint]ones should not be recommended as a pleural sclerosing agent, when a pleurodesis is attempt.

DISCLOSURE: Lisete Teixeira, None.

Renam U. Bumlai Francisco S. Vargas MD Milena M. Acencio BS Leila Antonangelo MD Gabriela G. Carnevale PharmD Evaldo Marchi MD Lisete R. Teixeira MD * Pulmonary Division, Heart Institute (InCor), Sat Paulo Medical School, Sat Paulo, Brazil

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Clarithromycin
Home Contact Resources Exchange Links ebay